Prognostic value of PIK3CA mutations in HER2-positive early stage breast cancer: A French cohort study.

被引：0
|
作者：
Coussy, Florence
Lehmann-Che, Jacqueline
Sanna, Alice
Giacchetti, Sylvie
Bertheau, Philippe
Cuvier, Caroline
Lalloum, Marjorie
Poirot, Brigitte
de Roquancourt, Anne
Bouhidel, Fatiha
Rigon, Matthieu Resche
Espie, Marc
Teixeira, Luis
de Cremoux, Patricia
机构：
[1] Hop St Louis, Breast Dis Ctr, Paris, France
[2] St Louis Hosp, Mol Oncol Unit, Paris, France
[3] Paris Diderot Univ, Paris, France
[4] Hop St Louis, Dept Biostat, Paris, France
[5] Hop St Louis, Dept Pathol, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11607
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
  • [2] PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
    Guarneri, V.
    Dieci, M. V.
    Bisagni, G.
    Brandes, A. A.
    Frassoldati, A.
    Cavanna, L.
    Musolino, A.
    Giotta, F.
    Rimanti, A.
    Garrone, O.
    Bertone, E.
    Cagossi, K.
    Nanni, O.
    Piacentini, F.
    Orvieto, E.
    Curtarello, M.
    Chic, N.
    D'Amico, R.
    Prat, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S23 - S23
  • [3] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [5] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [6] Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
    Zouein, Joseph
    Noujaim, Charbel
    Kourie, Hampig Raphael
    BIOMARKERS IN MEDICINE, 2021, 15 (09) : 609 - 613
  • [7] Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis
    Shi, Qiyun
    Xuhong, Juncheng
    Tian, Hao
    Qu, Man
    Zhang, Yi
    Jiang, Jun
    Qi, Xiaowei
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
  • [8] Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer
    Reznitsky, Frances M.
    Jensen, Jeanette D.
    Knoop, Ann
    Jensen, Maj-Britt
    Laenkholm, Anne-Vibeke
    ACTA ONCOLOGICA, 2023, 62 (12) : 1913 - 1920
  • [9] Prognostic value of RAS, BRAF, and PIK3CA mutations in early-stage colorectal cancer.
    Byer, Jennifer Elizabeth
    Kothari, Nishi
    Juan, TzuHua
    Teer, Jamie K.
    Schell, Michael J.
    Shibata, David
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis
    Seo, Y. -J.
    Yu, J. -H.
    Kim, S. -W.
    Lee, J. -E.
    Nam, S. -J.
    Cho, S. -Y.
    Cho, E. -Y.
    VIRCHOWS ARCHIV, 2017, 471 : S61 - S61
12345